[go: up one dir, main page]

BR0201691A - Derivados de tiazol - Google Patents

Derivados de tiazol

Info

Publication number
BR0201691A
BR0201691A BR0201691-5A BR0201691A BR0201691A BR 0201691 A BR0201691 A BR 0201691A BR 0201691 A BR0201691 A BR 0201691A BR 0201691 A BR0201691 A BR 0201691A
Authority
BR
Brazil
Prior art keywords
formula
compounds
syndrome
pharmaceutical compositions
conditions
Prior art date
Application number
BR0201691-5A
Other languages
English (en)
Inventor
Christopher Blair Cooper
Christopher John Helal
Mark Allen Sanner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0201691A publication Critical patent/BR0201691A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

"DERIVADOS DE TIAZOL". A invenção refere-se a compostos com a fórmula 1 em que R^ 1^, R^ 3^, e R^ 4^ sejam tal como definidos, e os seus sais farmaceuticamente aceitáveis. Os compostos com a fórmula 1 são indicados como tendo atividade de inibição de cdk5, cdk2, e GSK-3. Descrevem-se composições farmacêuticas e métodos incluindo compostos com a fórmula 1 para se tratarem doenças e condições que incluam o crescimento anormal de células, tais como o câncer, e doenças neurodegenerativas e condições e os que são afetados pela neurotransmissão da dopamina são descritos. Também são descritas composições farmacêuticas e métodos que incluem compostos com a fórmula 1 para tratar a fertilidade masculina e a mobilidade do esperma; o diabetes mellitus; impedimento da tolerância à glicose ; síndrome metabólica ou síndrome X; síndrome de ovário policístico; adipogênese e obesidade; miogênese e fragilidade, por exemplo, a diminuição do desempenho físico relacionada com o envelhecimento; sarcopenia aguda, por exemplo, atrofia muscular e/ou caquexia associada a queimaduras, condição acamado, imobilização de membros, ou cirurgia maior torácica, abdominal, e/ou ortopédica; sepsia; queda de cabelo, diminuição da espessura do cabelo, e calvície; e imunodeficiência.
BR0201691-5A 2001-05-11 2002-05-13 Derivados de tiazol BR0201691A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29046601P 2001-05-11 2001-05-11

Publications (1)

Publication Number Publication Date
BR0201691A true BR0201691A (pt) 2003-03-11

Family

ID=23116124

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0201691-5A BR0201691A (pt) 2001-05-11 2002-05-13 Derivados de tiazol

Country Status (9)

Country Link
US (2) US6720427B2 (pt)
EP (1) EP1256578B1 (pt)
JP (1) JP2002338556A (pt)
AT (1) ATE315555T1 (pt)
BR (1) BR0201691A (pt)
CA (1) CA2385692A1 (pt)
DE (1) DE60208630T2 (pt)
ES (1) ES2254611T3 (pt)
MX (1) MXPA02004790A (pt)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL370989A1 (en) * 2001-12-21 2005-06-13 Novo Nordisk A/S Amide derivatives as gk activators
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
MXPA05000130A (es) * 2002-06-27 2005-02-17 Novo Nordisk As Derivados de aril-carbonilo como agentes terapeuticos.
AU2003252715B2 (en) 2002-07-30 2009-06-04 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
AU2003288956A1 (en) * 2002-10-30 2004-06-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
AU2004212490B2 (en) 2003-02-10 2008-05-15 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CN1794988B (zh) * 2003-03-31 2010-07-28 株式会社·R-技术上野 用于治疗血管渗透性过高疾病的组合物
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
WO2004108133A2 (en) * 2003-06-05 2004-12-16 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
WO2005014591A1 (en) * 2003-07-15 2005-02-17 L'oreal 2-acylamino or 2-sulfonylamino-1, 3-thiazoles as couplers for the oxidation dyeing of keratin fibres
FR2857664B1 (fr) * 2003-07-15 2007-12-14 Oreal Nouveaux derives thiazoles et utilisation de ces derives pour la teinture des fibres keratiniques
PL1723128T3 (pl) * 2004-01-06 2013-04-30 Novo Nordisk As Pochodne heteroarylowe mocznika oraz ich zastosowanie jako aktywatory glukokinazy
EP1709019B1 (en) * 2004-01-12 2007-08-08 Applied Research Systems ARS Holding N.V. Thiazole derivatives and use thereof
CA2567569A1 (en) * 2004-05-21 2006-01-26 Banyu Pharmaceutical Co., Ltd. Selective inhibitors against cdk4 and cdk6 having aminothiazole skeleton
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
US7888346B2 (en) * 2004-09-24 2011-02-15 Universtiy of Maryland, Baltimore Method of treating organophosphorous poisoning
MX2007004358A (es) * 2004-10-14 2007-07-17 Abbott Gmbh & Co Kg Compuestos de azabicicloheptilo adecuados para tratar trastornos que responden a la modulacion del receptor de dopamina d3.
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
JP2008526721A (ja) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するチアゾールおよびイソチアゾール誘導体
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
US7777040B2 (en) * 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
ATE547396T1 (de) * 2005-07-08 2012-03-15 Novo Nordisk As Dicycloalkylcarbamoyl-harnstoffe als glucokinase- aktivatoren
US7884210B2 (en) * 2005-07-14 2011-02-08 Novo Nordisk A/S Ureido-thiazole glucokinase activators
JP4689393B2 (ja) * 2005-07-29 2011-05-25 株式会社資生堂 毛髪はり・こし改善剤および毛髪用化粧料
JP4646739B2 (ja) * 2005-08-29 2011-03-09 株式会社資生堂 毛髪はり・こし改善剤および毛髪用化粧料
US20090233975A1 (en) * 2005-07-29 2009-09-17 Masaru Suetsugu Hair resiliency/body improver and hair cosmetic
US20070105920A1 (en) * 2005-11-08 2007-05-10 Akzo Nobel N.V. 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
ES2344751T3 (es) * 2005-11-08 2010-09-06 N.V. Organon Derivados de 2-(benzoimidazol-1-il)-n-(4-feniltiazol-2-il)acetamida utiles en el tratamiento de trastornos relacionados con trpv1.
WO2007054480A1 (en) * 2005-11-08 2007-05-18 N.V. Organon 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
AU2007207743B2 (en) * 2006-01-18 2010-07-08 Amgen Inc. Thiazole compounds as protein kinase B (PKB) inhibitors
EP1849785A1 (en) * 2006-04-28 2007-10-31 Neuropharma, S.A. N-(2-Thiazolyl)-amide derivatives as GSK-3 inhibitors
EP2016075A1 (en) * 2006-05-03 2009-01-21 AstraZeneca AB Thiazole derivatives and their use as anti-tumour agents
US20080242694A1 (en) * 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
US8252749B2 (en) * 2006-09-28 2012-08-28 Follica, Inc. Methods, kits, and compositions for generating new hair follicles and growing hair
AU2007312165A1 (en) * 2006-10-21 2008-04-24 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
US8138185B2 (en) * 2007-01-09 2012-03-20 Novo Nordisk A/S Urea glucokinase activators
EP2099777B1 (en) * 2007-01-11 2015-08-12 Novo Nordisk A/S Urea glucokinase activators
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
GB0701426D0 (en) * 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
WO2008128986A1 (en) * 2007-04-18 2008-10-30 Probiodrug Ag Urea derivatives as glutaminyl cyclase inhibitors
US20100278784A1 (en) * 2007-05-15 2010-11-04 Puretech Ventures Methods and compositions for treating skin conditions
WO2009011871A2 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
CA2692713A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
CN101835765B (zh) * 2007-08-03 2013-05-29 罗马克实验室有限公司 烷基磺酰基取代的噻唑化物类化合物
WO2009027732A1 (en) * 2007-08-24 2009-03-05 Astrazeneca Ab 5-6-bicyclic heteroaromatic compounds with antibacterial activity
UY31545A1 (es) 2007-12-20 2009-08-03 Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20110263647A1 (en) 2009-01-15 2011-10-27 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
JPWO2010125799A1 (ja) * 2009-04-27 2012-10-25 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有するウレア誘導体
UA107791C2 (en) * 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
AP3074A (en) 2009-05-12 2014-12-31 Romark Lab Lc Haloalkyl heteroaryl benzamide compounds
PT2445349T (pt) 2009-06-26 2022-05-16 Romark Laboratories Lc Compostos e métodos para tratamento da gripe
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
CA2789014C (en) * 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
EP2377850A1 (en) * 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
JP5998142B2 (ja) 2010-09-27 2016-09-28 アボット ゲーエムベーハー ウント カンパニー カーゲー 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのその使用
CN105360132A (zh) 2010-11-03 2016-03-02 陶氏益农公司 杀虫组合物和与其相关的方法
JP2014500275A (ja) 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
AR088082A1 (es) * 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
PH12014500930A1 (en) 2011-10-26 2014-06-09 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9282739B2 (en) 2012-04-27 2016-03-15 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9708288B2 (en) 2012-04-27 2017-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US8901153B2 (en) 2012-04-27 2014-12-02 Dow Agrosciences, Llc. Pesticidal compositions and processes related thereto
EP2880448B1 (en) 2012-08-03 2022-06-29 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
ES2881081T3 (es) 2013-03-15 2021-11-26 Agenebio Inc Procedimientos y composiciones para mejorar la función cognitiva
JP2016535010A (ja) 2013-10-17 2016-11-10 ダウ アグロサイエンシィズ エルエルシー 有害生物防除性化合物の製造方法
CA2925595A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
MX2016004940A (es) 2013-10-17 2016-06-28 Dow Agrosciences Llc Proceso para la preparacion de compuestos plaguicidas.
CN105636445B (zh) 2013-10-17 2018-12-07 美国陶氏益农公司 制备杀虫化合物的方法
WO2015058021A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
CA2925952A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
EP3057426A4 (en) 2013-10-17 2017-03-29 Dow AgroSciences LLC Processes for the preparation of pesticidal compounds
NZ719541A (en) 2013-10-22 2017-11-24 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
EP3060050A4 (en) 2013-10-22 2017-04-05 Dow AgroSciences LLC Synergistic pesticidal compositions and related methods
WO2015061163A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Pesticidal compositions and related methods
JP2016535025A (ja) 2013-10-22 2016-11-10 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
JP2016536307A (ja) 2013-10-22 2016-11-24 ダウ アグロサイエンシィズ エルエルシー 農薬組成物および関連する方法
TW201519786A (zh) 2013-10-22 2015-06-01 陶氏農業科學公司 殺蟲組成物及相關方法（一）
EP3062619B1 (en) 2013-10-22 2019-07-24 Dow AgroSciences LLC Pesticidal compositions and related methods
AU2014340412B2 (en) 2013-10-22 2017-04-20 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
JP2016534068A (ja) 2013-10-22 2016-11-04 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
JP2016538265A (ja) 2013-10-22 2016-12-08 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
NZ719754A (en) 2013-10-22 2017-06-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
JP2016535024A (ja) 2013-10-22 2016-11-10 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
KR20160074640A (ko) 2013-10-22 2016-06-28 다우 아그로사이언시즈 엘엘씨 살충 조성물 및 관련 방법
CA2926433A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Pesticidal compositions and related methods
MX2016005310A (es) 2013-10-22 2016-08-08 Dow Agrosciences Llc Composiciones pesticidas sinergicas y metodos relacionados.
KR20160074581A (ko) 2013-10-22 2016-06-28 다우 아그로사이언시즈 엘엘씨 상승작용적 살충 조성물 및 관련 방법
NZ720023A (en) 2013-10-22 2017-09-29 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
JP2017523168A (ja) 2014-07-31 2017-08-17 ダウ アグロサイエンシィズ エルエルシー ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの製造方法
KR20170039121A (ko) 2014-07-31 2017-04-10 다우 아그로사이언시즈 엘엘씨 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법
CN106488909A (zh) 2014-07-31 2017-03-08 美国陶氏益农公司 制备3‑(3‑氯‑1h‑吡唑‑1‑基)吡啶的方法
KR20170042714A (ko) 2014-08-19 2017-04-19 다우 아그로사이언시즈 엘엘씨 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법
JP2017528469A (ja) 2014-09-12 2017-09-28 ダウ アグロサイエンシィズ エルエルシー ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの調製方法
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
WO2017087486A1 (en) * 2015-11-16 2017-05-26 Ohio State Innovation Foundation Methods and compositions for treating disorders and diseases using survival motor neuron (smn) protein
BR112019008372B1 (pt) 2016-12-29 2021-11-09 Dow Agrosciences Llc Processo para preparação de compostos pesticidas
WO2018125817A1 (en) 2016-12-29 2018-07-05 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
EP3679027A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydrobenzimidazolones
EP4487909A3 (en) 2018-06-12 2025-03-19 vTv Therapeutics LLC Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
WO2020047229A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
MA56193A (fr) * 2019-06-14 2022-04-20 Ifm Due Inc Composés et compositions pour traiter des états associés à une activité de sting
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CA3194868A1 (en) * 2020-10-16 2022-04-21 Georg Winter Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
WO2022150585A1 (en) 2021-01-08 2022-07-14 Ifm Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
IL308314A (en) 2021-05-07 2024-01-01 Kymera Therapeutics Inc CDK2 compounds and their uses
WO2024231436A1 (en) * 2023-05-11 2024-11-14 Arxada Ag Hydrogenation of cyclic ketones
WO2025137622A1 (en) * 2023-12-22 2025-06-26 Ganymede Oncology, Inc. Amidocycloalkylene nrf2 protein degraders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821239A (en) * 1966-04-05 1974-06-28 Rhone Progil Certain n-thiazol-2-ylureas
US6054475A (en) * 1996-11-20 2000-04-25 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituted dihydrobenzofuran-based phosphodiesterase 4 inhibitors useful for treating airway disorders
HUP0000321A3 (en) * 1996-12-24 2000-09-28 Chugai Pharmaceutical Co Ltd Aromatic amine derivatives having nos inhibitory effect, process for producing them and pharmaceutical compositions containing them
US6020335A (en) * 1997-02-06 2000-02-01 Pfizer Inc (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
ATE288904T1 (de) * 1998-06-18 2005-02-15 Bristol Myers Squibb Co Durch kohlenstoff substituierte aminothiazole als inhibitoren von zyclin-abhägigen kinasen
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents

Also Published As

Publication number Publication date
US6720427B2 (en) 2004-04-13
DE60208630D1 (de) 2006-04-06
ES2254611T3 (es) 2006-06-16
MXPA02004790A (es) 2003-02-11
EP1256578A1 (en) 2002-11-13
US20040192746A1 (en) 2004-09-30
JP2002338556A (ja) 2002-11-27
ATE315555T1 (de) 2006-02-15
DE60208630T2 (de) 2006-08-17
CA2385692A1 (en) 2002-11-11
US20030078252A1 (en) 2003-04-24
EP1256578B1 (en) 2006-01-11

Similar Documents

Publication Publication Date Title
BR0201691A (pt) Derivados de tiazol
YU14703A (sh) Derivati pirazola i njihova upotreba kao inhibitora protein kinaze
EA200300097A1 (ru) Производные имидазола
ATE557030T1 (de) Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung
NO20064412L (no) Kondensert heterocykelderivat, medisinsk sammensetning inneholdende det samme og medisinsk anvendelse derav
DK1317459T3 (da) Bicykliske pyrrolylamider som glucogenphosphorylase-inhibitorer
BRPI0416212A (pt) derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação
NO20055680L (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
EA200501936A1 (ru) Производные пиридо[2,1-a]изохинолина в качестве ингибиторов dpp-iv
NO20073465L (no) Benzotiazol-derivater
NO20053748L (no) Pyrrolopyridazinderivater.
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
GB9024730D0 (en) Diazine derivatives
NO20082445L (no) Neuropeptid-2 reseptor-agonister
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav
TW200616985A (en) Salicylthiazoles substituted by diphenylamine or diphenylamine derivatives, process for their preparation and their use
CA2534634A1 (en) Azolidinecarbonitriles and their use as dpp-iv inhibitors
PT1157015E (pt) Utilizacao de sistemas 2-amino-triazole policiclicos para a preparacao de medicamentos para tratamento de perturbacoes lipometabolicas, da obesidade e da diabetes tipo ii
DK1218401T3 (da) 4-Benzylaminoquinolin-konjugat med galdesyre og deres heteroanaloger, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
ATE440835T1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
DE60106246D1 (de) Malto-oligosaccharide und deren verwendung
PE20030337A1 (es) Indan-1-onas sustituidas en c2 y sus derivados, procedimiento para su preparacion y su utilizacion como medicamentos
BR0008559A (pt) Aminas tiazol-2-ilideno policìclicas, processos paraa sua preparação e seu emprego comomedicamento

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2055 DE 25/05/2010.